# Interleukin-12 Plus Interleukin-2 in Treating Patients With Advanced Solid Tumors

> **NCT00005604** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 25 (actual)

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **BIOLOGICAL:** recombinant interleukin-12
- **BIOLOGICAL:** aldesleukin
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00005604
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-03
- **Primary completion:** 2003-07
- **Final completion:** —
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2013-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005604, "Interleukin-12 Plus Interleukin-2 in Treating Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00005604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*